OncoCyte Corporation (NYSE MKT:OCX) Q2 2020 Earnings Conference Call - Final Transcript

Jul 29, 2020 • 04:30 pm ET

Previous

OncoCyte Corporation (NYSE MKT:OCX) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Greetings, and welcome to Oncocyte Corporation Second Quarter 2020 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

It's now my pleasure to introduce your host, Bob Yedid, Managing Director of LifeSci Advisors. Thank you. You may begin.

Executive
Robert Yedid

Thank you, Doug, and thank you, everyone, for joining us for today's conference call to discuss Oncocyte's Second Quarter 2020 Financial Results and Recent Operating Highlights. If you have not seen today's financial results press release, please visit the company's website and look at the Investors page.

Before turning the call over to Ronnie Andrews, Oncocyte's President and Chief Executive Officer, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. We encourage you to review the company's SEC filings, including, without limitation, the company's Form 10-K and Form 10-Qs, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need to obtain third-party reimbursement for patients' use of any diagnostic test the company commercializes, our need and ability to obtain future capital and maintenance of intellectual property rights and uncertainties associated with COVID-19 pandemic and its possible effects on our operations. Therefore, actual results -- actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Oncocyte expressly disclaims any intent or obligation to update these forward-looking statements except as otherwise may be required under applicable law.

With that said, it's my pleasure to turn the call over to Ronnie Andrews, CEO. Ronnie?

Executive
Ronald Andrews

Thanks, Bob, and welcome, everyone, to our conference call to discuss our second quarter 2020 financial results and operating highlights. Joining me today on the call are Mitch Levine, Chief Financial Officer; Al Parker, Chief Operating Officer; Dr. Doug Ross, our Chief Medical Officer; and Padma Sundar, our SVP of Commercial. We'll all be available during the question-and-answer session.

The second quarter of 2020 has been an important chapter in the evolution of Oncocyte. My goal for the call today is to do a brief high-level review of the DetermaDx technical overview performed since our call in June and spend the majority of our time sharing the tremendous progress we've experienced on our 2 commercially available high-impact tests that are both at revenue generation phase and have significant revenue upside, given the large and untapped markets they will serve and to provide additional clarity around DetermaIO and its value to Oncocyte today.

When I agreed to step into the CEO role a year ago, the mission was to diversify Oncocyte by adding high-value cancer tests. We're at